Before s.c. injection of tumor cells, FGFR2+ cells accounted for about 1.08 ± 0.50%, 2.50 ± 0.32% and 1.06 ± 0.58% in P1, P2, and P3, respectively. The gene discussed is FGFR2; the disease is neoplasm.